MEDP

MEDP (Medpace Holdings, Inc.) Analyst Note Date: 2026-06-13 Current Price: $460.20

1. Structural Readiness

State: Context-Only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 3.4% (Productive)

Analysis:

2. Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Platforms, Tools & CRO/CDMO (Tier Direct, Confidence High). Exposure: MEDP is a direct beneficiary of the secular growth in clinical development, specifically within the Metabolic (GLP-1 adjacent) and Oncology therapeutic areas.

Thesis Weighting: The company is positioned as a "Quality Compounder" within the CRO/CDMO space. The thesis is driven by the increasing complexity of drug development and the outsourced nature of clinical trials. MEDP's specific exposure to Metabolic, Oncology, CNS, and AVAI (Antiviral/Anti-infective) areas aligns directly with the highest growth segments of the biotech sector. The evidence indicates that growth in the Metabolic and Oncology areas was a primary driver of recent performance, reinforcing the direct link to the GLP-1 and broader biotech innovation wave. The company's focus on "scientifically-driven" services and its ability to navigate regulatory processes for complex trials provides a structural moat that supports the "Tier Direct" classification.

3. Business Analysis

Business Model & Industry: Medpace Holdings, Inc. operates as a Contract Research Organization (CRO), providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company functions across the entire product lifecycle, from Phase I trials through Phase IV post-market surveillance.

Key Operational Metrics (as of Q1 2026):

• Revenue Growth: Q1 2026 revenue was $706.6 million, representing a 26.5% year-over-year increase.
• Backlog Strength: As of March 31, 2026, the backlog stood at $2.929 billion, an increase of 2.9% from the prior year.
• Revenue Visibility: Management projects that approximately $1.94 billion of the backlog will convert to revenue in the next 12 months.
• New Business Awards: Net new business awards in Q1 2026 were $618.4 million, up 23.7% year-over-year.
• Book-to-Bill: The net book-to-bill ratio for the quarter was 0.88.
• Customer Base: The company maintains a diversified base, with 82% of net revenue in 2025 derived from small biopharmaceutical companies and 13% from mid-sized companies. The top 5 and top 10 customers represented roughly 28% and 37% of the last 12 months' revenue, respectively.
• Margins: Q1 2026 EBITDA margin was 21.1%, slightly down from 21.2% in the prior year, as higher reimbursable costs were offset by lower employee-related costs.
• Guidance: Management has maintained its 2026 guidance ranges for revenue, EBITDA, net income, and EPS, based on an effective tax rate of 19% to 20% and interest income of $27.5 million.

4. Archetype and Conviction

Archetype: Quality Compounder. Fit: The company fits the "Quality Compounder" archetype due to its consistent revenue growth (26.5% YoY), strong backlog accumulation ($2.9B), and high-quality customer mix (dominated by small-to-mid biotechs which drive innovation). The "Quality" aspect is supported by the high conversion rate of backlog (23.3% in Q1) and the ability to maintain margins despite cost fluctuations.

Conviction Stack:

• Thesis Strength: High. The secular tailwinds in biotech and the specific focus on high-growth therapeutic areas (Metabolic, Oncology) provide a robust foundation.
• Evidence Quality: Strong. The evidence base is rich with primary data from earnings transcripts and SEC filings, providing clear visibility into backlog, revenue, and new awards.
• Structural Quality: Moderate to High. The backlog-to-revenue conversion ratio and the book-to-bill ratio (0.88) indicate healthy demand, though the book-to-bill being slightly below 1.0 suggests a need for continued strong new business awards to sustain growth.
• Rerating Potential: Moderate. The market may re-rate the stock if the book-to-bill ratio improves above 1.0 consistently or if the backlog conversion rate accelerates beyond historical norms.

5. Invalidation, Strengthening, and Gaps

Invalidation Triggers:

• A sustained decline in the backlog conversion rate below historical norms (e.g., dropping significantly below the 23.3% Q1 rate).
• A significant deterioration in the book-to-bill ratio (falling well below 0.88) indicating a slowdown in new business awards.

Strengthening Factors:

• An increase in the book-to-bill ratio above 1.0, indicating that new awards are outpacing revenue recognition.
• Expansion of EBITDA margins beyond 21.1%, demonstrating operational leverage.
• Continued growth in the Metabolic and Oncology therapeutic areas, which are the primary drivers of recent performance.

Evidence Gaps:

• Forward Guidance Nuance: While guidance is unchanged, the specific breakdown of how the $27.5 million interest income and tax rate assumptions impact the bottom line in the context of potential macroeconomic shifts is not detailed in the provided evidence.
• Customer Concentration Risk: While the top 10 customers represent 37% of revenue, the specific exposure to any single large client in the current quarter is not detailed, which could be a risk if a major client delays trials.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: High Key evidence: Q1 2026 revenue growth of 26.5% YoY to $706.6M; Backlog of $2.9B with $1.94B expected to convert in 12 months; Strong new business awards of $618.4M (+23.7% YoY) driven by Metabolic and Oncology. Key risks: Book-to-bill ratio below 1.0 (0.88) indicating potential slowdown in new awards; Customer concentration with top 10 clients at 37% of revenue; Potential margin compression if reimbursable costs rise faster than employee cost savings. Sizing hint: Position size should reflect the high conviction in the business fundamentals while acknowledging the lack of a defined technical entry point; consider scaling in as a technical structure forms. Expected path: Management expects revenue and earnings to grow in line with the current backlog conversion and guidance; the company will likely continue to see strong demand in Metabolic and Oncology trials. Expected horizon: 12 to 18 months for the current backlog to convert and for new awards to drive the next growth cycle. Failure mode to watch: A sustained drop in the backlog conversion rate or a significant decline in new business awards that pushes the book-to-bill ratio significantly lower.